Trial Profile
A Phase II Study With Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Jul 2022
Price :
$35
*
At a glance
- Drugs Orteronel (Primary)
- Indications Advanced breast cancer; Bone metastases; Male breast cancer
- Focus Therapeutic Use
- 20 May 2021 Status changed from active, no longer recruiting to completed.
- 15 Mar 2021 Planned End Date changed from 1 Dec 2020 to 1 Jun 2021.
- 15 Mar 2021 Planned primary completion date changed from 1 Dec 2020 to 1 Jun 2021.